Clinical Trials Directory
We are doing this study to find out if neratinib combined with palbociclib is better than neratinib alone when it comes to treating HER2-positive tumors.
We are doing this study to learn more about how right hemisphere brain damage (RHD) from a stroke can affect people's ability to communicate. We want to improve treatments to help stroke survivors regain their ability to communicate.
We are doing this study to identify new signs and symptoms of inflammatory bowel disease (IBD) in children and young adults. We want to improve at predicting the future course of IBD so that we can treat it better and faster. We also hope this study will help us learn how IBD develops so that we can make new treatments for IBD.
We are doing this study to learn if SAPIEN 3 valve system is safe and will work with adults and children who have a dysfunctional right ventricular outflow tract (RVOT) conduit or have an implanted valve in the pulmonic position.
Patients will first get Td preconditioning and a medicine called temozolomide for 5 days. On day 21, they will get the study vaccine, PEP-CMV. The first 3 vaccines will be given every 2 weeks. After that, the vaccines will be given once a month. The first treatment cycle lasts 77 days, and all cycles after that last 28 days. To join the study, patients must have lab and clinical tests done within 7 days before starting. Lab results must be no more than 7 days old when therapy begins. If therapy starts within 7 days of the lab tests, the tests do not need to be repeated.
People in this study will visit the research center two times each month to see the study doctor. The study can last up to 2 years. Treatment happens in cycles, and each cycle is 28 days long, which is about 4 weeks. A person can have up to 26 cycles, which equals about 2 years of treatment. The amount of medicine given will depend on the person’s weight, which is checked before each new cycle. The medicine is called tocilizumab. It blocks a protein called interleukin-6, which causes swelling in the body. This medicine is usually used for diseases where the immune system attacks the body, like arthritis, and it can also help with a problem called cytokine release syndrome after certain cancer treatments.
We are doing this study to learn how to best support young women making decisions about breast cancer surgery. We want to know what makes women feel uncertain about their decision-making so we can become better at providing the information they need. This study involves testing a web-based decision support tool that is designed to help young women with newly diagnosed breast cancer with their surgical decisions.